These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16110311)

  • 1. Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells.
    Irie A; Matsumoto K; Anderegg B; Kuruma H; Kashani-Sabet M; Scanlon KJ; Uchida T; Baba S
    Cancer Gene Ther; 2006 Mar; 13(3):298-305. PubMed ID: 16110311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation.
    Shono T; Tofilon PJ; Schaefer TS; Parikh D; Liu TJ; Lang FF
    Cancer Res; 2002 Feb; 62(4):1069-76. PubMed ID: 11861384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
    Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
    Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer therapy using combined proliferating cell nuclear antigen antisense oligonucleotides and recombinant adenovirus p53.
    Zhu Z; Xing S; Lin C; Zhang X; Fu M; Liang X; Zeng F; Lu G; Wu M
    Chin Med J (Engl); 2003 Dec; 116(12):1860-3. PubMed ID: 14687474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.
    Komata T; Kondo Y; Koga S; Ko SC; Chung LW; Kondo S
    Gene Ther; 2000 Dec; 7(24):2071-9. PubMed ID: 11223987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional gene therapy with rAAV-wt-p53 enhanced the efficacy of cisplatin in human bladder cancer cells.
    Ruifa H; Liwei L; Binxin L; Ximing L
    Urol Int; 2006; 77(4):355-61. PubMed ID: 17135787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A preclinical model of minimal residual cancer in the muscle highlights challenges associated with adenovirus-mediated p53 gene transfer.
    Oakley R; Phillips E; Hooper R; Wilson D; Partridge M
    Clin Cancer Res; 2002 Jun; 8(6):1984-94. PubMed ID: 12060644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model.
    Li Z; Rakkar A; Katayose Y; Kim M; Shanmugam N; Srivastava S; Moul JW; McLeod DG; Cowan KH; Seth P
    Gene Ther; 1998 May; 5(5):605-13. PubMed ID: 9797864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer.
    Rizk NP; Chang MY; El Kouri C; Seth P; Kaiser LR; Albelda SM; Amin KM
    Cancer Gene Ther; 1999; 6(4):291-301. PubMed ID: 10419047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy.
    Pagliaro LC; Keyhani A; Williams D; Woods D; Liu B; Perrotte P; Slaton JW; Merritt JA; Grossman HB; Dinney CP
    J Clin Oncol; 2003 Jun; 21(12):2247-53. PubMed ID: 12805322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of adenoviral-mediated p53 gene transfer is synergistically enhanced by combined use of antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.
    Miyake H; Yamanaka K; Muramaki M; Hara I; Gleave ME
    Neoplasia; 2005 Feb; 7(2):171-9. PubMed ID: 15802022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.
    Lipinski KS; Djeha AH; Krausz E; Lane DP; Searle PF; Mountain A; Wrighton CJ
    Gene Ther; 2001 Feb; 8(4):274-81. PubMed ID: 11313801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The levels of integrin alpha v beta 5 may predict the susceptibility to adenovirus-mediated gene transfer in human lung cancer cells.
    Takayama K; Ueno H; Pei XH; Nakanishi Y; Yatsunami J; Hara N
    Gene Ther; 1998 Mar; 5(3):361-8. PubMed ID: 9614556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector.
    Gibson SA; Pellenz C; Hutchison RE; Davey FR; Shillitoe EJ
    Clin Cancer Res; 2000 Jan; 6(1):213-22. PubMed ID: 10656452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53).
    Yen N; Ioannides CG; Xu K; Swisher SG; Lawrence DD; Kemp BL; El-Naggar AK; Cristiano RJ; Fang B; Glisson BS; Hong WK; Khuri FR; Kurie JM; Lee JJ; Lee JS; Merritt JA; Mukhopadhyay T; Nesbitt JC; Nguyen D; Perez-Soler R; Pisters KM; Putnam JB; Schrump DS; Shin DM; Walsh GL; Roth JA
    Cancer Gene Ther; 2000 Apr; 7(4):530-6. PubMed ID: 10811470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5.
    Liu XY; Qiu SB; Zou WG; Pei ZF; Gu JF; Luo CX; Ruan HM; Chen Y; Qi YP; Qian C
    Mol Ther; 2005 Apr; 11(4):531-41. PubMed ID: 15771956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of viral vectors: gene transfer efficiency and tissue specificity in a bladder cancer model.
    Siemens DR; Crist S; Austin JC; Tartaglia J; Ratliff T
    J Urol; 2003 Sep; 170(3):979-84. PubMed ID: 12913754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas.
    Benítez JA; Arregui L; Vergara P; Segovia J
    Cancer Gene Ther; 2007 Oct; 14(10):836-46. PubMed ID: 17599090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An agent that increases tumor suppressor transgene product coupled with systemic transgene delivery inhibits growth of metastatic lung cancer in vivo.
    Kataoka M; Schumacher G; Cristiano RJ; Atkinson EN; Roth JA; Mukhopadhyay T
    Cancer Res; 1998 Nov; 58(21):4761-5. PubMed ID: 9809972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers.
    Clayman GL; Frank DK; Bruso PA; Goepfert H
    Clin Cancer Res; 1999 Jul; 5(7):1715-22. PubMed ID: 10430074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.